Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiogenomic Biomarkers for Early Treatment Response in High Risk Prostate Cancer
NCT05477823Phase 1Active, not recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- Mar 2023
- Primary completion
- Apr 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in prostate cancer (PCa), sponsored by University of Wisconsin–Madison. Primary endpoint: Imaging markers for mid-treatment response at 3 months. Started Mar 2023; status: active, not recruiting.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05477823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05477823.